Acute kidney injury following radical nephrectomy and inferior vena cava thrombectomy: A tertiary referral center experience [0.03%]
肾切除和下腔静脉切术后急性肾损伤：一家三级转诊中心的体会
Alireza Ghoreifi,John V Dudinec,Michael C Ivey et al.
Alireza Ghoreifi et al.
Purpose: To investigate the incidence and determine the risk factors associated with acute kidney injury (AKI) following radical nephrectomy with inferior vena cava (IVC) thrombectomy. ...
Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients [0.03%]
血红蛋白、白蛋白、淋巴细胞、血小板评分（HALP）在预测膀胱癌新辅助化疗疗效中的应用及意义
Max H Stempel,John P Quezada,Brie Belz et al.
Max H Stempel et al.
Objective: To determine the utility of hemoglobin, albumin, lymphocyte, platelet (HALP) score in stratifying muscle-invasive bladder cancer (MIBC) patients according to their response to neoadjuvant chemotherapy (NAC) pri...
Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study [0.03%]
达尔鲁单抗联合多西他赛、雄激素受体通路抑制剂和多西他赛在转移性激素敏感型前列腺癌患者中的无进展生存期：一项真实世界多中心回顾性研究
Emily Rinderknecht,Gloria Bielstein,Richard Cathomas et al.
Emily Rinderknecht et al.
Background and objective: In metastatic hormone-sensitive prostate cancer (mHSPC), first-line treatment with either docetaxel + androgen deprivation therapy (ADT) or androgen receptor pathway inhibitors (ARPI) + ADT repre...
Sean R Miller,Yuni Dewaraja,Steven P Rowe et al.
Sean R Miller et al.
Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the advantages of systemic therapy with tar...
Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma [0.03%]
恩沃单抗治疗后晚期尿路上皮癌的局部治疗模式
Betty Wang,Laura Davis,Amanda Nizam et al.
Betty Wang et al.
Background: Enfortumab vedotin (EV) + pembrolizumab (P) is now first-line standard-of-care for locally advanced or metastatic urothelial carcinoma (la/mUC) after the phase 3 EV-302 trial doubled overall survival (OS) vs. ...
Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis [0.03%]
针对HER2阴性和低表达的局部晚期或转移性尿路上皮癌患者，使用德瓦鲁单抗治疗的效果：系统评价和Meta分析
Jianjun Ye,Yanxin Li,Mengni Zhang et al.
Jianjun Ye et al.
While disitamab vedotin (DV) shows promising efficacy in HER2-positive locally advanced/metastatic urothelial carcinoma (la/mUC), its clinical efficacy in HER2-negative and HER2-low (immunohistochemistry [IHC] 0 and 1+) populations is uncle...
Clinical stage IIA/B embryonal carcinoma predominant nonseminomatous germ cell tumor: Minimizing treatment burden [0.03%]
以胚胎细胞瘤为主的临床分期IIA/ B期非精原细胞睾丸癌的减量化治疗
Jiping Zeng,Parth Thakker,Timothy A Masterson et al.
Jiping Zeng et al.
Purpose: Embryonal carcinoma predominance (ECP) in the orchiectomy specimen is linked to a higher risk of retroperitoneal and systemic relapse. Both chemotherapy and primary retroperitoneal lymph node dissection (RPLND) a...
Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway [0.03%]
优化高级别非肌层浸润性膀胱癌的治疗效果：外科主导治疗路径的影响
Pietro Scilipoti,Giuseppe Rosiello,Alfonso Santangelo et al.
Pietro Scilipoti et al.
Introduction: The management of high-grade non-muscle invasive bladder cancer (HG-NMIBC) is complex, requiring accurate transurethral resection of bladder tumors (TURBT), intravesical therapy, and diligent follow-up. We h...
Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial [0.03%]
膀胱癌伴瘤的最优辅助治疗方案——随机对照试验的肿瘤结局和患者报告结果
Amr A Elsawy,Mahmoud Laymon,Osama Ezzat et al.
Amr A Elsawy et al.
Background: Adjuvant Intravesical BCG and chemotherapy are utilized viables options for intermediate-risk (IR) NMIBC. We are lacking well-designed evidence for superiority of any in terms of effectiveness, toxicity, and p...
Estimating the prevalence of germline mutations in DNA mismatch repair genes among patients with upper tract urothelial carcinoma: a systematic review and meta-analysis [0.03%]
错配修复基因林奇综合征胚系突变在上尿路上皮癌中的发病风险系统评价和 Meta 分析
Joseph Moryousef,Braden Millan,Piotr Zareba
Joseph Moryousef
Background: Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline mutations in the DNA mismatch repair (MMR) genes MSH2, MSH6, MLH1 and PMS2. The objective of this systematic review was to estim...